Top Markets
#1 NKN NKN +148.63%
#2 Black Phoenix Black Phoenix +99.30%
#3 Codatta Codatta +29.58%
#4 SAFEcoin SAFEcoin +28.41%
#5 Bluwhale Bluwhale +27.83%
#6 Saakuru Saakuru +24.27%
#7 StakeStone StakeStone +22.52%
#8 Particle Network Particle Network +17.58%
#9 Yooldo Games Yooldo Games +16.68%
#10 Arcblock Arcblock +16.01%
Coin of the day
NKN NKN
Settings
Language
ENGLISH
Currency
USD
Theme
Intellipharmaceutics International Inc. Intellipharmaceutics International Inc.

Intellipharmaceutics International Inc.

IPCIF
Rank in Stocks #99999
Intellipharmaceutics International Inc., a pharmaceutical company, researches,... Intellipharmaceutics International Inc., a pharmaceutical company, researches, develops, and manufactures novel and generic controlled-release and targeted-release oral solid dosage drugs in the United States. It develops various drug delivery systems, product candidates, and a pipeline of products based on its patented Hypermatrix technology in various therapeutic areas, including neurology, cardiovascular, gastrointestinal tract, diabetes, and pain. The company offers Focalin XR, a dexmethylphenidate hydrochloride extended-release capsule for hyperactivity disorder; Keppra XR, a levetiracetam extended-release tablet for the treatment of partial onset seizures in patients with epilepsy; Effexor XR, a venlafaxine hydrochloride extended-release capsule to treat depression; and Protonix, a pantoprazole sodium delayed-release tablet to treat gastroesophageal reflux disease. It also provides Glucophage XR, a metformin hydrochloride extended-release tablet that treats type 2 diabetes; Seroquel XR, a quetiapine fumarate extended-release tablet for the treatment of schizophrenia, bipolar disorder, and major depressive disorders; Lamictal XR, a lamotrigine extended release tablet to treat epilepsy; Pristiq, a desvenlafaxine extended-release tablet to treat depression; Coreg CR, a carvedilol phosphate extended-release capsule for heart failure and hypertension; and Ranexa, a ranolazine extended release tablet for chronic angina. In addition, the company is developing OxyContin, an oxycodone hydrochloride controlled-release capsule for pain; OxyContin, an oxycodone hydrochloride controlled-release capsule for pain; and Regabatin XR, a pregabalin extended-release capsule for the management of neuropathic pain. It has a license and commercialization agreement with Par Pharmaceutical Inc. The company was founded in 1998 and is based in Toronto, Canada.
Share Price
$0.15
Market Cap
$4.96M
Change (1 day)
0.00%
Change (1 year)
0.00%
Country
CA
Trade Intellipharmaceutics International Inc. (IPCIF)

Category

Healthcare
Number of shares outstanding for Intellipharmaceutics International Inc. (IPCIF)
Number of shares outstanding as of August 2023: 33.09M
According to Intellipharmaceutics International Inc. latest financial reports and stock price the company's current number of shares outstanding is 33.09M. At the end of November 2021 the company had 29.43M shares outstanding. The number of outstanding shares is usually impacted by stock plits and shares buy back.
Shares outstanding history for Intellipharmaceutics International Inc. (IPCIF) from 1999 to 2026
Shares Outstanding at the end of each year
Year Shares Outstanding Change
2026 (TTM) 33.09M 0.00%
2022 33.09M 12.45%
2021 29.43M 24.90%
2020 23.56M 9.18%
2019 21.58M 353.15%
2018 4.76M 53.55%
2017 3.10M 16.16%
2016 2.67M 12.34%
2015 2.38M 3.11%
2014 2.31M 17.18%
2013 1.97M 13.98%
2012 1.73M 15.10%
2011 1.50M 37.47%
2010 1.09M -51.30%
2008 2.24M 13.63%
2007 1.97M 124.16%
2006 879.29K 10.85%
2005 793.22K 15.41%
2004 687.29K 11.69%
2003 615.38K 27.29%
2002 483.46K 7.69%
2001 448.93K 2.77%
2000 436.82K 49.40%
1999 292.38K 0.00%
Shares Outstanding for similar companies or competitors
Company Shares Outstanding Difference Country
Novo Nordisk A/S Novo Nordisk A/S
Novo Nordisk A/S
NVO.US
 4.45B 13,340.60%
DK
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 253.90M 667.24%
US
Regeneron Pharmaceuticals, Inc. Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
REGN.US
 102.90M 210.95%
US
UCB SA UCB SA
UCB SA
UCB.BR
 190.00M 474.14%
BE
Argenx SE Argenx SE
Argenx SE
ARGX.US
 61.42M 85.60%
NL